The gross margin of Swedish biopharmaceutical company Sobi was down at the lowest point in 2011 at 51 percent, but then generally increased the following years. In 2021, the gross margin of Sobi stood at 78 percent. The company's full name is Swedish Orphan Biovitrum AB. Sobi is specialized on the treatment of rare diseases.
Profit from the additional features of your individual account
Currently, you are using a shared account. To use individual functions (e.g., mark statistics as favourites, set
statistic alerts) please log in with your personal account.
If you are an admin, please authenticate by logging in again.